Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.
Advanced Cancer|Lung Cancer|Head and Neck Cancer|Melanoma
DRUG: EOS-448|DRUG: pembrolizumab|DRUG: inupadenant|DRUG: Dostarlimab|DRUG: SOC chemotherapies
Percentage of participants with DLT and Adverse Events, From first study treatment administration through Day 21-28 for DLT / Up to 120 days after the last dose|Recommended Phase 2 dose (RP2D) of EOS884448 in participants with advanced solid tumors, Up to 48 weeks|Percentage of participants with Objective Response as determined by Investigator, Until disease progression - Approximately 48 months
Duration of Response (DOR), Until disease progression or death - Approximately 48 months|Disease Control Rate (DCR), Until disease progression or death - Approximately 48 months|Progression-free-survival (PFS), Until disease progression or death - Approximately 48 months|Mean and median Maximum concentration (Cmax) of EOS884448 at each dose level, Up to 48 weeks|Percentage of participants with anti-drug antibodies to EOS884448, Up to 48 weeks
The combinations evaluated will be:

* EOS-448 combined with pembrolizumab, an anti-PD-1 antibody
* EOS-448 combined with inupadenant an investigational adenosine A2A receptor antagonist
* EOS-448 combined with dostarlimab an anti-PD-1 antibody
* inupadenant combined with dostarlimab
* EOS-448 combined with inupadenant and dostarlimab
* EOS-448 combined with dostarlimab and standard of care chemotherapies in participants with NSCLC